Embed Size (px)
DESCRIPTION
Citation preview
Examples of NINDS Funding Opportunity Announcements
Cooperative Program(U01, U54, U44)
Exploratory Translational Grants (R21)
Tool Compound Discovery (R01)
Tool CompoundOptimization (R01)
Phase I Trials
Target ID Assay Screening Hit to LeadProof
ofConcept
Pre-clinical
SafetyLead
Optimization
Rebecca [email protected]
Contacts: David [email protected]
Molecular Libraries HTS Services
Screening centers offer: Technical assistance in adapting assays for HTS
Technical assistance for developing screening plan
Library screening with your assay
Med chem optimization of your probe
… AT NO COST TO YOU!
http://mli.nih.gov/mli/
Assay Screening Hit to Lead
Provides FREE ACCESS to contract services for:
● Production/bulk supply
● GMP manufacturing
● Formulation
● Pharmacokinetic testing
● Animal toxicology
● Manufacture of clinical trial supplies
● Product development planning and advice in IND preparation
http://nctt.nih.gov/bridgs
Bridging Interventional Development Gaps (BrIDGs)
Pre-clinical Safety
Blueprint Neurotherapeutics Network
• Goal: phase I clinical success
• Any nervous system indication
• “Virtual pharma” structure
• Free access to drug development services + funding for biology
• For novices and experts seeking additional capacity
• PI retains control of IP
Lead Development Team
MedicinalChemistry
PK/ToxPhase ITrials
Bioactivity/EfficacyStudies
Principal investigator Industry consultants
NIH staff
GMP/Formulation
NIH ContractsU01s
Blueprint NeuRx
Phase I Trials
Pre-clinical
SafetyLead
Optimization
Current Projects
Blueprint NeuRxBlueprint Neurotherapeutics Network
Principal Investigator Institution Disorder
John Bixby University of Miami Optic Neuropathy
Raymond J. Dingledine Emory University Stroke
Marcie A. Glicksman Brigham and Women’s Hospital ALS
Michael Lark Trevena, Inc. Depression
Konstantin Petrukhin Columbia University Macular Degeneration
Edwin W. Rubel University of Washington Hearing Loss
Steven Lee Wagner UC San Diego Alzheimer’s
Disease biology• Novel target for the disease• Strong biological validation• Feasible path to the clinic
Assays• Robust in vitro assay for optimization• Strong confirmatory assays
Compounds• Amenable to chemistry• IP free of obvious roadblocks
Deadline:June 2012
Entry Criteria
Blueprint NeuRxBlueprint Neurotherapeutics Network
Jill [email protected] [email protected]
vhttp://neuroscienceblueprint.nih.gov/bpdrugs/
Contact Program Staff
Rebecca [email protected]
?Provide the following info to help NIH staff help you:
• Where does your project fall within the discovery/development pipeline?
• What is the disease indication?
• What kind of therapeutic are you developing (drug, biologic, device, etc.)?
• Would you prefer to do the work yourself or utilize NIH research services?
